Is NGL Fine Chem overvalued or undervalued?

As of 30 June 2025, the valuation grade for NGL Fine Chem has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 32.44, an EV to EBITDA ratio of 21.16, and a ROE of 7.38%.
In comparison to its peers, NGL Fine Chem's PE ratio is lower than Sun Pharma's 35.22 and Divi's Lab's 82.67, both of which are considered expensive. However, it is higher than Cipla's attractive PE of 23.06, suggesting that while NGL Fine Chem is fairly valued, it may not offer as much value as some of its peers. Notably, the company's stock has underperformed significantly over the past year, with a return of -53.44% compared to the Sensex's 5.79%, reinforcing the cautious outlook on its valuation.